Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Signaling in leukemia: which messenger to kill?
Warren S. Pear
Warren S. Pear
View: Text | PDF
Commentary

Signaling in leukemia: which messenger to kill?

  • Text
  • PDF
Abstract

Authors

Warren S. Pear

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
TEL/PDGFβR leukemogenesis is influenced by phosphotyrosine interactions....
TEL/PDGFβR leukemogenesis is influenced by phosphotyrosine interactions. At the left is 1 chain of PDGFβR, showing tyrosine residues that become phosphorylated after ligand binding. The signaling complex is a dimer (only 1 chain is shown). Strongly interacting proteins are shown adjacent to the tyrosine residues to which they bind. As shown by STAT and PI3K, proteins can interact with multiple tyrosines. The right panels show TEL/PDGFβR and the mutant proteins analyzed by Tomasson et al. (2). Only tyrosine residues that were mutated in their work are shown. The phenotypes of mice receiving the wild-type and mutant constructs are listed below each construct. “ΔPNT” indicates deletion removing the pointed domain (indicated by the shaded box in TEL), which is necessary for oligomerization.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts